Medicenna Therapeutics to Participate in Two Healthcare Investor Conferences in February 2025
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in two major healthcare investor conferences in February 2025. The company will present at the Oppenheimer Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025, at 9:20 a.m. ET, with a webcast available for 180 days following the event.
Additionally, Medicenna will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference on Friday, February 28, 2025, in New York City. The company's management team will be available for one-on-one meetings with investors during both conferences. Interested investors can schedule meetings through conference representatives or by contacting Medicenna's investor relations team directly.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), una compagnia di immunoterapia in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a febbraio 2025. L'azienda presenterà all'Oppenheimer Annual Healthcare Life Sciences Conference martedì 11 febbraio 2025, alle 9:20 a.m. ET, con una web conference disponibile per 180 giorni dopo l'evento.
Inoltre, Medicenna parteciperà a un incontro informale al B. Riley Securities Precision Oncology & Radiopharma Conference venerdì 28 febbraio 2025, a New York City. Il team di gestione dell'azienda sarà disponibile per incontri individuali con gli investitori durante entrambe le conferenze. Gli investitori interessati possono pianificare incontri tramite i rappresentanti della conferenza o contattando direttamente il team delle relazioni con gli investitori di Medicenna.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), una empresa de inmunoterapia en fase clínica, ha anunciado su participación en dos importantes conferencias para inversores en el sector de la salud en febrero de 2025. La empresa presentará en la Conferencia de Ciencias de la Vida en Salud Anual de Oppenheimer el martes 11 de febrero de 2025, a las 9:20 a.m. ET, con una transmisión en línea disponible durante 180 días después del evento.
Además, Medicenna participará en una charla informal en la Conferencia de Oncología de Precisión y Radioterápia de B. Riley Securities el viernes 28 de febrero de 2025, en la ciudad de Nueva York. El equipo de gestión de la empresa estará disponible para reuniones individuales con inversores durante ambas conferencias. Los inversores interesados pueden programar reuniones a través de representantes de la conferencia o contactando directamente al equipo de relaciones con inversores de Medicenna.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF)는 임상 단계의 면역 요법 회사로 2025년 2월에 열리는 두 개의 주요 의료 투자자 회의에 참가한다고 발표했습니다. 이 회사는 2025년 2월 11일 화요일 오전 9시 20분 ET에 Oppenheimer 연례 생명과학 의료 회의에서 발표하며, 행사 이후 180일 동안 웹캐스트가 제공될 예정입니다.
또한 Medicenna는 2025년 2월 28일 금요일 뉴욕시에서 열리는 B. Riley Securities 정밀 온코로지 및 방사선 약리학 회의에서 파이어사이드 채팅에 참여합니다. 회사의 경영 팀은 두 회의 동안 투자자와의 일대일 미팅을 위해 대기하고 있습니다. 관심 있는 투자자는 회의 대표를 통해 미팅을 예약하거나 Medicenna의 투자자 관계 팀에 직접 연락할 수 있습니다.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), une société d'immunothérapie en phase clinique, a annoncé sa participation à deux grandes conférences pour investisseurs en santé en février 2025. La société présentera à la Conférence Annuelle Oppenheimer sur les Sciences de la Vie en Santé le mardi 11 février 2025 à 9h20 ET, avec un webinaire disponible pendant 180 jours après l'événement.
De plus, Medicenna participera à une discussion informelle lors de la Conférence sur l'Oncologie de Précision et les Radiopharmaceutiques de B. Riley Securities le vendredi 28 février 2025, à New York. L'équipe de direction de l'entreprise sera disponible pour des réunions individuelles avec les investisseurs pendant les deux conférences. Les investisseurs intéressés peuvent planifier des réunions par l'intermédiaire des représentants de la conférence ou en contactant directement l'équipe des relations avec les investisseurs de Medicenna.
Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), ein Unternehmen für Immuntherapie in klinischen Phasen, hat seine Teilnahme an zwei bedeutenden Investorenkonferenzen im Gesundheitswesen im Februar 2025 angekündigt. Das Unternehmen wird am Dienstag, den 11. Februar 2025, um 9:20 Uhr ET auf der Oppenheimer Annual Healthcare Life Sciences Conference präsentieren, wobei ein Webcast für 180 Tage nach der Veranstaltung verfügbar sein wird.
Darüber hinaus wird Medicenna an einem Fireside-Chat auf der B. Riley Securities Precision Oncology & Radiopharma Conference am Freitag, den 28. Februar 2025, in New York City teilnehmen. Das Management-Team des Unternehmens wird während beider Konferenzen für persönliche Meetings mit Investoren zur Verfügung stehen. Interessierte Investoren können Meetings über die Konferenzvertreter anfragen oder das Investor-Relations-Team von Medicenna direkt kontaktieren.
- None.
- None.
TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also host one-on-one meetings with investors during these events.
Oppenheimer Annual Healthcare Life Sciences Conference 2025
Format: Presentation
Date: Tuesday, February 11, 2025, at 9:20 a.m. ET
Webcast link: https://wsw.com/webcast/oppenheimer39/mdna/2754560
Webcast and replay information for this event will be available on the investor relations section of Medicenna’s website on the Events & Presentations page. The webcast replay will be available for 180 days following the event.
B. Riley Securities Precision Oncology & Radiopharma Conference 2025
Format: Fireside Chat
Date: Friday, February 28, 2025
Location: New York City, NY
One-on-One Investor Meetings
In addition to the presentations, Medicenna’s management team will be available for one-on-one meetings with investors at both conferences. Investors interested in scheduling a meeting can contact their respective conference representatives or reach out to Medicenna’s investor relations team at ir@medicenna.com.
About Medicenna Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. MDNA11 is being evaluated in the Phase 1/2 ABILITY-1 Study (NCT05086692) as a monotherapy and in combination with pembrolizumab. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna’s early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically “cold” tumors.
For more information, please visit www.medicenna.com, and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.
This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.
Investor Contact:
Christina Cameron
Investor Relations
ir@medicenna.com
(647) 953-0673
FAQ
When is Medicenna Therapeutics (MDNAF) presenting at the Oppenheimer Healthcare Conference 2025?
How long will the MDNAF Oppenheimer Conference webcast be available for replay?
Where can investors access the webcast for MDNAF's Oppenheimer Conference presentation?
When and where is MDNAF participating in the B. Riley Securities Conference 2025?
How can investors schedule one-on-one meetings with MDNAF management at these conferences?
